<i>IDH</i>-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
Lih En Hong, Mihir D. Wechalekar, Monika Kutyna, Annabelle Small, Kelly Lim, Chloe Thompson-Peach, Joule J. Li, Rakchha Chhetri, Hamish S. Scott, Anna Brown, Christopher N Hahn, David T Yeung, Salvia Sajid, Nirmal Robinson, Ranjeny Thomas, Susan Branford, Richard J. D’Andrea, Saumya E. Samaraweera, Mrinal M. Patnaik, Susanna Proudman, Danièl Thomas, Chung Hoow Kok, Mithun Vinod Shah, Devendra Hiwase
Abstract
ABSTRACT: High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.